Understanding how TDP-43 protein affects brain cells in neurodegenerative diseases
Official title: Deciphering TDP-43 Proteinopathy: Unveiling the Consequences on Oligodendrocyte Dysfunction
Funded at University of Pennsylvania · NIH-10883862 · Data updated 2026-11-12
This study is looking at how clumps of a protein called TDP-43 affect a special type of brain cell, which could help us understand diseases like ALS and Alzheimer's better and find new ways to treat them.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 15, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $787,095 |
| NIH project number | 1R21AG087070-01 |
| Project ID | NIH-10883862 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with neurodegenerative diseases such as ALS, Alzheimer's, or related conditions.
✕Less likely to help
Patients with neurodegenerative diseases not associated with TDP-43 pathology may not benefit from this research.
What this research studies
This research investigates the role of TDP-43 protein aggregates in causing dysfunction in oligodendrocytes, a type of brain cell, which is linked to various neurodegenerative diseases such as ALS and Alzheimer's. The researchers will create laboratory models to explore how these protein aggregates spread and impact brain function. By examining the effects of TDP-43 on brain cells, the study aims to uncover the underlying mechanisms of these diseases and identify potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of neurodegenerative diseases.
How similar studies have gone: Previous research has shown that targeting protein aggregates in neurodegenerative diseases can lead to significant advancements, suggesting this approach may also yield valuable insights.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Porta Antolinez, Silvia — University of Pennsylvania
- Study coordinator: Porta Antolinez, Silvia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.